ALNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Alnylam Pharmaceuticals's Capital Expenditure for the three months ended in Dec. 2023 was $-15.31 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-116.40 Mil.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
The historical data trend for Alnylam Pharmaceuticals's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Capex-to-Operating-Income | Get a 7-Day Free Trial | - | - | - | - | - |
Alnylam Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Capex-to-Operating-Income | Get a 7-Day Free Trial | - | - | - | 0.08 | - |
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Capex-to-Operating-Income falls into.
Alnylam Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-62.211) | / | -282.175 | |
= | N/A |
Alnylam Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as
Capex-to-Operating-Income | = | - Capital Expenditure | / | Operating Income |
= | - (-15.309) | / | -116.404 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (NAS:ALNY) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael W Bonney | director | 65 HAYDEN AVE, LEXINGTON MA 02421 |
Pushkal Garg | officer: CMO & EVP Dev & Med Affairs | C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472 |
Akshay Vaishnaw | officer: SVP, Clinical Research | 300 THIRD STREET, CAMBRIDGE MA 02139 |
Yvonne Greenstreet | officer: EVP, Chief Commercial Officer | PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Jeffrey V. Poulton | officer: Chief Financial Officer | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Tolga Tanguler | officer: EVP, Chief Commercial Officer | 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142 |
Indrani Lall Franchini | officer: EVP, CLO & Secretary | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
Peter N Kellogg | director | MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
Carolyn R Bertozzi | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Dennis A Ausiello | director | PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
Phillip A Sharp | director | BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John Maraganore | director, officer: President and CEO | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Laurie Keating | officer: SVP,GC & Secretary | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Steven M Paul | director | C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285 |
From GuruFocus
By Marketwired • 10-17-2023
By GuruFocus Research • 11-02-2023
By Business Wire • 01-02-2024
By Business Wire • 12-13-2023
By Business Wire • 10-09-2023
By Business Wire • 08-25-2023
By Marketwired • 11-06-2023
By Business Wire • 12-06-2023
By Business Wire • 08-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.